E
Bio-Rad Laboratories, Inc. BIOB
NYSE
Recommendation
Prev Close
$234.41
Volume
--
Avg Vol (90D)
35
Market Cap
$6.90B
Dividend & Yield
--
52-Week Range
$225.29 - $359.22
P/E (TTM)
--
EPS (TTM)
-$65.04
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Bio-Rad to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
4/15/2025 - Business Wire
Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results
2/13/2025 - Business Wire
Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies
2/13/2025 - Business Wire
Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025
1/27/2025 - Business Wire
Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests
1/8/2025 - Business Wire
Bio-Rads Management to Host Investor Meetings at J.P. Morgan's 43rd Annual Healthcare Conference
1/2/2025 - Business Wire
Bio-Rads Management to Host Investor Meetings at Citi's 2024 Global Healthcare Conference
11/21/2024 - Business Wire
Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference
10/31/2024 - Business Wire
Bio-Rad Reports Third-Quarter 2024 Financial Results
10/30/2024 - Business Wire
Bio-Rad to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024
10/14/2024 - Business Wire
Bio-Rads Management to Participate in Fireside Chat During Wells Fargos 2024 Healthcare Conference
8/22/2024 - Business Wire
Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer
8/20/2024 - Business Wire
Bio-Rad Reports Second-Quarter 2024 Financial Results
8/1/2024 - Business Wire
Bio-Rad to Report Second Quarter Financial Results on Thursday, August 1, 2024
7/17/2024 - Business Wire
Bio-Rad Names Anette Engelhardt Executive Vice President and President of Clinical Diagnostics Group
5/30/2024 - Business Wire
Bio-Rads Management to Participate in Fireside Chat During Jefferies Global Healthcare Conference
5/23/2024 - Business Wire
Bio-Rad Reports First-Quarter 2024 Financial Results
5/7/2024 - Business Wire
Bio-Rads Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference
5/1/2024 - Business Wire
Bio-Rad Announces Life Science Group Management Changes
4/26/2024 - Business Wire
Income Statement
Total Revenue (TTM)
$2.57B
EBITDA (TTM)
$426.40M
EBIT (TTM)
$274.80M
Net Income (TTM)
-$1.84B
Balance Sheet
Total Assets (Q)
$9.36B
Total Debt (Q)
$1.37B
Total Liabilities (Q)
$2.79B
Book Value Per Share (Q)
$234.52
Cash Flow
Cash from Operations (TTM)
$455.20M
Cash from Investing (TTM)
-$160.20M
Cash from Financing (TTM)
-$218.80M
Net Change in Cash (TTM)
$85.40M
Filings
Filing Date
Friday, February 14, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
0.15
7-Day Total Return
7.41%
30-Day Total Return
-8.96%
60-Day Total Return
-32.23%
90-Day Total Return
-28.21%
Year to Date Total Return
-25.68%
1-Year Total Return
-13.55%
2-Year Total Return
-47.86%
3-Year Total Return
-55.05%
5-Year Total Return
-42.79%
52-week Low
Apr 09, 2025 - $225.29
52-week High
Jan 29, 2025 - $359.22
Valuation
Market Cap
$6.90B - Mid Cap
Enterprise Value
$6.61B
Price/Sales (TTM)
2.56
Price/Book (Q)
1.00
Dividends and Shares
Shares Outstanding
28.00M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.bio-rad.com
Phone Number
510 724 7000
Address
1000 Alfred Nobel Drive
Hercules, CA 94547
Country
United States
Year Founded
1952
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through... more